Editas Medicine, Inc. Common Stock (EDIT)

Price$3.35

Favorite Metrics

Price vs S&P 500 (26W)-22.78%

Price vs S&P 500 (4W)37.58%

Market Capitalization$329.83M

All Metrics

Book Value / Share (Quarterly)$0.28

P/TBV (Annual)2.40x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)27.15%

Cash Flow / Share (Quarterly)$-1.69

Price vs S&P 500 (YTD)61.75%

Net Profit Margin (TTM)-395.01%

EPS (TTM)$-1.88

10-Day Avg Trading Volume1.69M

EPS Excl Extra (TTM)$-1.88

Revenue Growth (5Y)-14.89%

EPS (Annual)$-1.80

ROI (Annual)-186.35%

Net Profit Margin (5Y Avg)-639.39%

Cash / Share (Quarterly)$1.50

Revenue Growth QoQ (YoY)-19.16%

ROA (Last FY)-85.81%

Revenue Growth TTM (YoY)25.40%

EBITD / Share (TTM)$-1.77

ROE (5Y Avg)-180.58%

Operating Margin (TTM)-394.89%

Cash Flow / Share (Annual)$-1.69

P/B Ratio12.09x

P/B Ratio (Quarterly)7.33x

Net Income / Employee (Annual)$-2

EV / Revenue (TTM)5.97x

Net Interest Coverage (TTM)-121.78x

ROA (TTM)-74.23%

EPS Incl Extra (Annual)$-1.80

Current Ratio (Annual)3.54x

Quick Ratio (Quarterly)3.50x

3-Month Avg Trading Volume1.76M

52-Week Price Return155.30%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.41

P/S Ratio (Annual)8.14x

Asset Turnover (Annual)0.22x

52-Week High$4.54

Operating Margin (5Y Avg)-658.26%

EPS Excl Extra (Annual)$-1.80

CapEx CAGR (5Y)-38.95%

Tangible BV CAGR (5Y)11.63%

26-Week Price Return-18.80%

Quick Ratio (Annual)3.50x

13-Week Price Return58.22%

Total Debt / Equity (Annual)2.15x

Current Ratio (Quarterly)3.54x

Enterprise Value$241.789

Revenue / Share Growth (5Y)-21.67%

Asset Turnover (TTM)0.19x

Book Value / Share Growth (5Y)-46.38%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-395.01%

Cash / Share (Annual)$1.50

3-Month Return Std Dev91.60%

Net Income / Employee (TTM)$-2

ROE (Last FY)-586.56%

Net Interest Coverage (Annual)-43.22x

EPS Basic Excl Extra (Annual)$-1.80

Receivables Turnover (TTM)2.58x

Total Debt / Equity (Quarterly)2.15x

EPS Incl Extra (TTM)$-1.88

Receivables Turnover (Annual)2.58x

ROI (TTM)-182.26%

P/S Ratio (TTM)8.14x

Pretax Margin (5Y Avg)-639.39%

Revenue / Share (Annual)$0.46

Tangible BV / Share (Annual)$5.24

Price vs S&P 500 (52W)125.47%

Year-to-Date Return64.39%

5-Day Price Return16.61%

EPS Normalized (Annual)$-1.80

ROA (5Y Avg)-51.44%

Net Profit Margin (Annual)-395.01%

Month-to-Date Return36.44%

Cash Flow / Share (TTM)$-2.60

EBITD / Share (Annual)$-1.77

Operating Margin (Annual)-394.89%

LT Debt / Equity (Annual)1.96x

ROI (5Y Avg)-89.96%

LT Debt / Equity (Quarterly)1.96x

EPS Basic Excl Extra (TTM)$-1.88

P/TBV (Quarterly)2.40x

P/B Ratio (Annual)7.33x

Pretax Margin (TTM)-395.01%

Book Value / Share (Annual)$0.28

Price vs S&P 500 (13W)57.53%

Beta2.26x

Revenue / Share (TTM)$0.42

ROE (TTM)-523.29%

52-Week Low$1.18

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

3.67

3.70

3.75

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
EDITEditas Medicine, Inc. Common Stock	8.14x	25.40%	—	—	$3.35
AMGNAmgen Inc	5.13x	9.95%	73.30%	2.93%	$349.39
GILDGilead Sciences Inc	5.84x	2.40%	78.83%	133.64%	$138.55
ARGXargenx SE American Depositary Shares	12.46x	89.56%	150.91%	—	$828.35
BNTXBioNTech SE American Depositary Share	8.75x	-11.81%	84.21%	—	$102.12
BIIBBiogen Inc. Common Stock	2.60x	2.22%	75.69%	-18.77%	$176.02
MRNAModerna, Inc. Common Stock	11.02x	-39.93%	70.32%	—	$54.68
NBIXNeurocrine Biosciences Inc	4.49x	21.45%	98.18%	2.31%	$128.41
EXELExelixis Inc	4.96x	6.85%	96.39%	31.10%	$44.38
TECHBio-Techne Corp.	7.60x	1.64%	66.60%	-20.58%	$57.36
HALOHalozyme Therapeutics, Inc.	5.74x	37.55%	83.62%	22.89%	$66.64

About

Editas Medicine is a clinical-stage genome editing company developing CRISPR/Cas9-based therapeutics to treat serious genetic diseases. The company's proprietary platform uses a Cas9 enzyme-guide RNA complex to precisely repair disease-causing DNA mutations. Editas is advancing a pipeline of genome editing programs toward clinical and commercial applications.